Developing Breakthrough Biologics, Life-changing Medicines® Corporate Update June 10, 2025 Legal Notices The information in this slide deck is current as of June 10, 2025, unless otherwise noted, and is qualified in its entirety by reference to MacroGenics' Annual, Quarterly and Current Reports filed with the SEC. MacroGenics undertakes no obligation to update any of the information herein. Cautionary Note on Forward-Looking Statements Any statements in this presentation about future expectations, plans and ...

COMBINING TO CURE ® Forward-Looking Statements/Safe Harbor Arcus is at the forefront of designing combination therapies, with best-in-class potential, in the relentless pursuit of cures for cancer. Forward Looking Statements Safe Harbor: This presentation contains forward-looking statements about Arcus Biosciences, Inc. ("we," "Arcus" or the "Company") made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements regarding events or results to occur in t ...

Summary of Enovix Corporation (ENVX) Investor Conference Call - July 07, 2025 Company Overview - **Company**: Enovix Corporation (ENVX) - **Event**: Special Investor Conference Call - **Date**: July 07, 2025 Key Points Special Dividend Announcement - Enovix announced a special dividend in the form of tradable warrants for shareholders, with one warrant for every seven shares held as of July 17, 2025 [2][5] - Warrants will be distributed around July 21, 2025, and will trade on NASDAQ under the ticker symbol ENVXW [6] - Each warrant allows the purchase of one share at an exercise price of $8.75 before expiration [6] - The initiative is designed to align with shareholders and is non-dilutive, meaning no immediate dilution for existing shareholders [11][12] Financial Performance - Preliminary unaudited revenue for Q2 2025 was approximately $7.5 million, exceeding guidance of $4.5 million to $6.5 million due to increased product demand [10] - Cash and short-term investments were approximately $203 million at quarter-end [11] - If all warrants are exercised, the company expects to raise approximately $253.8 million, which will support the scale-up of manufacturing and other corporate purposes [21][14] Product Development and Market Position - Enovix launched the AI One platform, featuring the first artificial intelligence class batteries for smartphones, achieving an energy density of over 900 watt-hours per liter [7][8] - The AI One batteries meet performance requirements for fast charging and high cycle life, with initial shipments of 7,350 milliampere batteries to a leading smartphone OEM for qualification [9][10] - The company aims to lead the market in high energy density batteries, which are increasingly demanded due to AI applications in smartphones [7][9] Strategic Growth and Future Outlook - The dividend structure is designed to provide flexibility and control for shareholders, allowing them to hold, sell, or exercise their warrants without immediate dilution [12][13] - Enovix is fully funded for near-term milestones and believes the dividend will provide potential future access to capital for growth initiatives [14] - The company is focused on expanding its product offerings to meet diverse customer needs in the smartphone and broader technology markets [35] Additional Insights - The company is experiencing increased interest in its products, particularly in defense applications, and is evaluating opportunities for further investment in its Route J business [39][41] - The recent share buyback program is viewed as a tool for managing stock volatility and returning capital to shareholders [42][44] - Enovix emphasizes its commitment to building a battery platform for the next decade, aligning shareholder interests with company growth [47][48] This summary captures the essential information from the Enovix Corporation investor conference call, highlighting the company's strategic initiatives, financial performance, and product developments.

Financial Data and Key Metrics Changes - Net revenues for the first quarter were $7.1 million, down from $10 million in the prior year [6] - Average active brand partners decreased to 7,700 from 13,400 year-over-year [6] - Loss before income taxes improved to a negative $1.4 million from a negative $1.7 million [6] - Net loss decreased to $1.1 million compared to a loss of $1.3 million last year [6] - Loss per share improved to $0.13 from $0.15 on a fully diluted basis [6] - Net inventories decreased by $2.7 million from $44.7 million to $42 million [7] Business Line Data and Key Metrics Changes - The decline in sales was primarily driven by reduced brand partner levels in the paper pie division [4] - Customer sales events were implemented to promote paper pie sales and generate cash [4] Market Data and Key Metrics Changes - The company faced a challenging sales environment due to high inflation and reduced disposable income among families with small children [4] - The direct sales industry, particularly in the product sector, has experienced difficulties in recruiting new consultants [4] Company Strategy and Development Direction - The company is focusing on strategic changes to support brand partners and has launched new incentive programs [7] - A successful partnership with Ticket to Dream has allowed the company to distribute thousands of books to foster children [9] - The company is planning a phased approach to purchasing new titles and replenishing best sellers to energize the sales force [10][41] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the current downturn in the industry but expressed confidence in emerging stronger and more resilient [13] - The company is working on a sale leaseback of its headquarters, with expectations to complete the sale before September [12] - Management is optimistic about the ongoing sale process and has developed a contingency plan (Plan B) in case the primary sale does not go through [22][23] Other Important Information - The company has executed an agreement to sell the Hilti Complex, with a 90-day due diligence period [12] - Proceeds from the sale are expected to fully pay back the bank, leaving the company with no debt [13] Q&A Session Summary Question: What is the contingency plan if the sale of the Hilti Complex falls through? - Management has a viable Plan B that includes other offers with quick close contingencies, which would also help eliminate bank debt [22][23] Question: Can you provide more details about the buyer group for the Hilti Complex? - The buyer group is a real estate company, and management is optimistic about the ongoing due diligence process [26][27] Question: What is the strategy behind buying new titles given the current inventory levels? - The strategy involves a conservative approach to introduce new titles to energize the sales force without significantly increasing inventory levels [40][41] Question: What is the target net revenue run rate and average from partners during normalization? - Management indicated that rebuilding will take time, and they are implementing various strategies to improve sales and recruitment [44][45] Question: Has there been any serious interest in acquiring the company? - Management has not received any serious unsolicited offers for acquisition, but they would entertain such discussions in the future [47][50] Question: What is the current relationship with the bank? - The relationship has been good, with the bank supporting the company through the process, although amendments have become more restrictive [51][53]

Financial Data and Key Metrics Changes - Net revenues decreased to $7.1 million from $10 million in the prior year first quarter, representing a 29% decline [6] - Average active brand partners fell to 7,700 from 13,400, a decrease of 43% [6] - Loss before income taxes improved to a negative $1.4 million from a negative $1.7 million [6] - Net loss decreased to $1.1 million compared to a loss of $1.3 million last year [6] - Loss per share improved to $0.13 from $0.15 on a fully diluted basis [6] Business Line Data and Key Metrics Changes - The decline in sales was primarily driven by reduced brand partner levels in the paper pie division and ongoing customer sales events [4] - The company has seen a decline in brand partner levels due to high inflation and reduced disposable income among families with small children [4] Market Data and Key Metrics Changes - The direct sales industry, particularly in the product sector, is experiencing challenges in new consultant recruiting [4] - The company is facing a short-term impact on operating levels due to the current sales environment [4] Company Strategy and Development Direction - The company is focusing on strategic changes to support brand partners and has launched new incentive programs [7] - A sale leaseback of the headquarters is in progress, with expectations to complete the sale before September [13] - The proceeds from the sale are anticipated to fully pay back the bank, leaving the company with no debt [14] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging sales environment and the need for short-term tactics to generate cash [4] - There is confidence in executing either Plan A (sale of the building) or Plan B (alternative offers) by September [20] - Management is optimistic about the buyer group and believes they understand the local environment [22] Other Important Information - The company has launched a guest checkout feature to improve customer experience [9] - A successful partnership with Ticket to Dream has allowed the company to distribute thousands of books to foster children [10] Q&A Session Summary Question: What is the contingency plan if the building sale falls through? - Management has a viable Plan B that includes other offers with quick close contingencies, ensuring they can move forward without further delays [20][21] Question: Can you elaborate on the plan for new titles given the existing inventory levels? - The strategy involves a conservative approach to introducing new titles while replenishing best sellers, aimed at energizing the sales force without significantly increasing inventory [31] Question: What is the current banking relationship and future expectations? - The banking relationship has been supportive, with amendments becoming more restrictive to ensure cash flow for debt repayment, but there is no intention to maintain the same level of borrowing post-debt retirement [41]

Plug Power (PLUG) Update / Briefing July 07, 2025 04:15 PM ET Speaker0 Hello and welcome to today's Plug Power Investor Update Conference Call and Webcast. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to your host, Teal Hoyos, Vice President, Marketing and Communications. Please go ahead, Speaker1 Thank you. This call will include forwar ...

Summary of Royal Gold (RGLD) M&A Announcement Company and Industry - **Company**: Royal Gold (RGLD) - **Industry**: Gold streaming and royalty sector Core Points and Arguments 1. **Acquisition Announcement**: Royal Gold has entered into agreements to acquire Sandstorm Gold Royalties and Horizon Copper, aiming to create a premier growth company in the gold streaming and royalty sector [2][4] 2. **Strategic Growth**: The acquisitions align with Royal Gold's long-term strategy of growth through high-quality precious metals assets, enhancing its position as the only large-cap gold-focused streaming and royalty company domiciled in the U.S. [4][5] 3. **Portfolio Diversification**: The transactions will diversify Royal Gold's portfolio in terms of revenue and net asset value (NAV), adding immediate cash flow and substantial organic growth potential [5][22] 4. **Shareholder Benefits**: The addition of Sandstorm and Horizon assets is expected to be accretive to NAV and cash flow, enhancing long-term growth potential for Royal Gold shareholders [5][22] 5. **Transaction Structure**: The Sandstorm acquisition will be an all-share transaction, with Royal Gold shareholders owning 77% of the combined company, while the Horizon acquisition will be an all-cash transaction [11][12] 6. **Expected Growth**: The combined company is projected to increase 2025 gold equivalent ounces (GEO) production by approximately 26%, positioning for over 350,000 GEOs [22][23] 7. **Asset Quality**: The combined portfolio will include high-quality assets such as Antamina, Greenstone, and Fruta Del Norte, which are expected to provide significant growth and exploration upside [14][15][16] 8. **Market Position**: Post-acquisition, Royal Gold will have the largest and most diversified portfolio of mining assets in the streaming and royalty sector, with a focus on precious metals [24][28] 9. **Financial Position**: Royal Gold had no debt and a cash position of $241 million at the end of Q1, with plans to maintain a low debt-to-EBITDA ratio post-transaction [32][33] 10. **Investor Appeal**: The increased scale and liquidity from the transactions are expected to attract both passive and active investors, enhancing Royal Gold's market presence [31][34] Other Important Content 1. **Regulatory Approvals**: The transactions are subject to court and regulatory approvals, with expected closure in Q4 2025 [12][33] 2. **Simplification of Structure**: The integration of Sandstorm and Horizon will simplify the ownership structure, reducing overhead and legal complexities [29] 3. **Geographic Diversification**: The combined portfolio will maintain a strong focus on mining-friendly jurisdictions, with Canada and the U.S. representing 41% of NAV [27] 4. **Long-term Growth Potential**: The combined portfolio is expected to provide numerous growth opportunities, with 40 new revenue-producing assets and a total of 266 exploration stage assets [24][25] 5. **Market Sentiment**: There is a belief that the merger will lead to a revaluation of Royal Gold shares, benefiting Sandstorm shareholders as well [62]

Bexobrutideg Clinical Trial Updates - Bexobrutideg demonstrates rapid and durable clinical responses in relapsed/refractory CLL, with updated findings from an ongoing Phase 1a study presented at EHA 2025[5,9] - Bexobrutideg shows high clinical activity and tolerable safety in an ongoing Phase 1a/b study in patients with Waldenström macroglobulinemia (WM)[5,9] - In CLL patients, the objective response rate (ORR) was 80.9% (95% CI: 66.7–90.9), with 1 (2.1%) complete response (CR) and 37 (78.7%) partial responses (PR)[24] - In WM patients, the objective response rate (ORR) was 84.2%, with 2 (10.5%) very good partial responses (VGPR) and 11 (57.9%) partial responses (PR)[47] Bexobrutideg Safety and Tolerability - Bexobrutideg is well-tolerated in patients with relapsed/refractory CLL, with purpura/contusion (45.8%), diarrhea (31.3%), and fatigue (31.3%) being the most common treatment-emergent adverse events (TEAEs)[22] - In WM patients, the most common TEAEs were petechiae (27.3%), diarrhea (22.7%), and purpura/contusion (18.2%), with a favorable safety profile and no new safety signals[45] Bexobrutideg Mechanism and Market Potential - Bexobrutideg is a novel small molecule BTK degrader that can overcome treatment-emergent BTKi resistance mutations and disrupt BTK scaffolding[15,54] - The total BTKi sales were $10.6 billion in 2024 and projected worldwide sales for BTK-targeting agents in CLL are expected to exceed $15 billion by 2028[75] - Nurix is advancing bexobrutideg in CLL with a first pivotal study to be initiated in 2025, positioned to lead a new class of therapeutics in CLL[66] Regulatory Designations - Bexobrutideg has received U S Fast Track Designation from the FDA for CLL (January 2024) and WM (December 2024)[62,61] - Bexobrutideg has received EU PRIME designation from EMA in November 2024[62]

Barostim Device & Clinical Trial Results - Barostim improves exercise capacity in HFrEF patients, showing a 19%-20% improvement versus the control arm in clinical trials[19, 37] - The BeAT-HF pivotal trial demonstrated a clinically meaningful improvement of 60 meters in exercise capacity and a -14 point change in quality of life for Barostim patients[27, 28] - The BeAT-HF pivotal trial showed a 25% reduction in NT-proBNP levels with Barostim, which is considered clinically meaningful[34] Market Opportunity & Patient Identification - The initial annual market opportunity for Barostim in the U S and the five largest EU countries is estimated at $2 9 billion[44] - The U S market consists of 6 3 million patients, while the 5 EU countries have 8 6 million patients[42] - The initial addressable patient incidence rate is 55,000 patients per year in the U S and 61,000 patients per year in the 5 EU countries[42] - Patient identification for Barostim is straightforward, based on NYHA II/III symptoms, LVEF ≤ 35%, and NT-proBNP < 1600pg/ml[47] Commercial Strategy & Financial Performance - The company aims to add 3 new account managers every quarter to create new territories and activate implanting centers[58] - The goal is to have 5 active implanting centers per territory, with each center implanting 12 Barostim units per year[58] - Full year 2022 revenue was $7 0 million - $7 1 million, with US HF revenue at $5 9 million (+118%)[67] - The company projects total revenue between $35 0 million and $38 0 million for the full year of 2023[68]

Market Opportunity & Disease Burden - Heart failure affects over 6 million people in the U S [9], leading to over 1 1 million hospital discharges and over 1 3 million emergency room visits annually [11] - The annual costs associated with heart failure are expected to reach $70 billion by 2030 in the U S [11] - The U S annual net addressable market for Barostim is estimated at $2 2 billion, assuming an average selling price (ASP) of $29,000 [37] Barostim Therapy & Clinical Evidence - Barostim is presented as a neuromodulation therapy designed to improve heart failure symptoms [8] - Barostim implantation is a 60-minute procedure with a 97% freedom from major complications [46, 48] - Real-world evidence demonstrates an 85% relative reduction in hospital visits per year post-Barostim implant (average 1 92 years) compared to pre-implant (12 months) [67] Financial Performance & Guidance - Worldwide revenue for 2024 was $51 3 million, representing 31% growth [87, 88] - The gross margin for 2024 was 84% [87, 88] - The company's revenue guidance for full year 2025 is $55 0 – $58 0 million, with a gross margin of 83% – 84% and operating expenses of $95 0 – $98 0 million [90]